Biomarker developer strengthens team
Psynova in Cambridge, developing biomarkers for neuropsychiatric illnesses, has announced another addition to its board, Ian Ragan, as non-executive director.
His role will be to advise on the development and execution of Psynova’s R&D programmes and its business development activities.
With over 20 years experience of central nervous system drug discovery project management from basic research to clinical proof of concept, the trained biochemist has held many crucial roles.
These include executive director, biochemistry and molecular biology, at Merck’s UK research lab, executive director, neuroscience research, Europe for Eli Lilly and his most recent role as Lilly’s head of European scientific affairs.
Psynova was established last year by Dr Sabine Bahn and Prof Chris Lowe of the University of Cambridge, for the commercial development and exploitation of novel biomarkers for neuropsychiatric illnesses.
Building on 12 years of ground-breaking research by Dr Bahn, Psynova has close links with Bahn’s laboratory within the newly established Centre for Neuropsychiatric Research at the University of Cambridge.
Initially concentrating on schizophrenia and bipolar affective disorder – previously referred to as manic depression – Psynova intends to longer term, move into related therapeutic areas, such as depression, neurodegenerative disorders and substance abuse, as well as sleep and eating disorders, where it has extensive relevant expertise.
At present there are no validated biomarkers and diagnostics for these disorders. Nor are the underlying disease processes understood, meaning symptomatic relief only from current medications on offer.
Psynova intends to address all of these deficiencies.